All the news Showing 10 of 78 articles from: Triple therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/ribavirin for 24 weeks cures most genotype 3 hepatitis C patients, adding interferon may help difficult-to-treat Liz Highleyman / 14 November 2013 A dual oral regimen of sofosbuvir plus ribavirin led to sustained response for 93% of people with genotype 2 hepatitis C treated for 12 weeks and 85% of people with genotype 3 ... Faldaprevir plus pegylated interferon/ribavirin leads to early sustained response in people with HIV and HCV co-infection Liz Highleyman / 14 November 2013 The hepatitis C protease inhibitor faldaprevir plus pegylated interferon and ribavirin improved 4-week sustained response rates for HIV-positive people with genotype 1 hepatitis C co-infection in the STARTVerso4 trial, according to a ... Faldaprevir effective across patient sub-groups with several baseline characteristics associated with treatment outcomes Michael Carter / 14 November 2013 The experimental hepatitis C virus (HCV) protease inhibitor faldaprevir is efficacious across a range of subgroups of patients with genotype 1 infection, according to research presented to the recent Liver Meeting 2013, the ... Costs for Hepatitis C Treatment Skyrocket Medscape (requires registration) / 14 November 2013 Immunosuppression, EVR predictive of SVR in liver transplant recipients with HCV Healio Hepatology / 08 November 2013 High response rates with telaprevir triple therapy for HIV-positive men with acute hepatitis C Liz Highleyman / 05 November 2013 Adding telaprevir (Incivo or Incivek) to pegylated interferon and ribavirin shortens the duration of treatment and improves sustained response rates for HIV-positive men with acute hepatitis C virus (HCV) infection, according to ... Two new hepatitis C drugs recommended for US approval Keith Alcorn / 02 November 2013 Two new direct acting antiviral agents for the treatment of hepatitis C have been unanimously recommended for approval by expert advisory panels in the United States. Full marketing approval from the US ... US FDA approves twice-daily dosing for telaprevir (Incivek) FDA / 31 October 2013 FDA Panel Backs Sofosbuvir for Hepatitis C Medscape / 28 October 2013 Older people respond equally well to telaprevir triple therapy for hepatitis C Liz Highleyman / 24 October 2013 Interferon-based therapy with telaprevir (Incivo or Incivek) produced a similar cure rate with no notable increase in side-effects or treatment discontinuations for genotype 1 chronic hepatitis C patients over the age of 60, ... ← Prev12345...8Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive